VABRITZA
Live / Registered — Registered (as of 16 Dec 2025)
What this means for you
Registered since 16 Dec 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98590408
- Registration number
- 8064719
- Mark type
- Stylized text
- Filed
- 07 Jun 2024
- Published for opposition
- 28 Oct 2025
- Registered
- 16 Dec 2025
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 16 Dec 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 16 Dec 2025 — REGISTERED-PRINCIPAL REGISTER
- 28 Oct 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 28 Oct 2025 — PUBLISHED FOR OPPOSITION
- 22 Oct 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Sept 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Apr 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 07 Apr 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 07 Apr 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 07 Apr 2025 — NOTICE OF REVIVAL - E-MAILED
- 07 Apr 2025 — PETITION TO REVIVE-GRANTED
- 07 Apr 2025 — TEAS PETITION TO REVIVE RECEIVED
- 04 Apr 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 04 Apr 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 17 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED